Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al. use machine learning to impute baseline serostatus and determine vaccine efficacy by baseline serostatus, a...
Guardado en:
Autores principales: | , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1e68c8a00b6d4e3c8a2064bb9e95ef0a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:1e68c8a00b6d4e3c8a2064bb9e95ef0a |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:1e68c8a00b6d4e3c8a2064bb9e95ef0a2021-12-02T15:34:23ZRefined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning10.1038/s41467-018-06006-62041-1723https://doaj.org/article/1e68c8a00b6d4e3c8a2064bb9e95ef0a2018-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-06006-6https://doaj.org/toc/2041-1723Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al. use machine learning to impute baseline serostatus and determine vaccine efficacy by baseline serostatus, age and dengue serotype.I. DorigattiC. A. DonnellyD. J. LaydonR. SmallN. JacksonL. CoudevilleN. M. FergusonNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-9 (2018) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q I. Dorigatti C. A. Donnelly D. J. Laydon R. Small N. Jackson L. Coudeville N. M. Ferguson Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
description |
Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al. use machine learning to impute baseline serostatus and determine vaccine efficacy by baseline serostatus, age and dengue serotype. |
format |
article |
author |
I. Dorigatti C. A. Donnelly D. J. Laydon R. Small N. Jackson L. Coudeville N. M. Ferguson |
author_facet |
I. Dorigatti C. A. Donnelly D. J. Laydon R. Small N. Jackson L. Coudeville N. M. Ferguson |
author_sort |
I. Dorigatti |
title |
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
title_short |
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
title_full |
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
title_fullStr |
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
title_full_unstemmed |
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
title_sort |
refined efficacy estimates of the sanofi pasteur dengue vaccine cyd-tdv using machine learning |
publisher |
Nature Portfolio |
publishDate |
2018 |
url |
https://doaj.org/article/1e68c8a00b6d4e3c8a2064bb9e95ef0a |
work_keys_str_mv |
AT idorigatti refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning AT cadonnelly refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning AT djlaydon refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning AT rsmall refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning AT njackson refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning AT lcoudeville refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning AT nmferguson refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning |
_version_ |
1718386826871308288 |